SRTD Raises 31 Point 5 Million Euros for Selective RNA

Company SRTD Biotech Event Type Seed financing (€31.5 million) Modality Selectively expressed mRNA; fusogenic LNP Asset seRNA platform (preclinical) Target Disease-associated intracellular RNA markers Disease Area Oncology; autoimmune disease; fibrosis Summary Recovered source-gap item: SRTD Biotech completed an oversubscribed €31.5 million seed round announced November…

🔒

Continue reading this signal

Create a free InSilens account to unlock full articles, analysis, and deal context.

Create Free Account
Share this article :

Leave a Reply

Your email address will not be published. Required fields are marked *